NEW YORK (360Dx) – Seventh Sense Biosystems today announced that its TAP blood collection device has received CE marking.
The one-step, push-button device called Tap was cleared by the US Food & Administration in February 2017 and works by firing an array of microneedles into an individual's arm to collect capillary blood into a vacuum chamber. Receiving CE marking allows Seventh Sense, based in Medford, Massachusetts to being commercializing Tap in Europe.
The company received a $2 million investment from Ionis Pharmaceuticals last October.